Ethylene Oxide Residue Testing for Silver-Containing Collagen Wound Dressings

Ethylene oxide residue testing is a critical quality and safety control for silver-containing collagen wound dressings that are terminally sterilized with EO gas. This article explains the residual analytes of concern (EO and ethylene chlorohydrin), the applicable limits under ISO 10993-7 and GB/T 16886.7, the headspace gas chromatography methods used by accredited third-party laboratories, and how the results support batch release, sterilization validation, and regulatory submissions.

Technical Overview

Silver-containing collagen wound dressings combine a collagen matrix, which supports hemostasis and granulation tissue formation, with an antimicrobial silver component such as silver ions, silver nanoparticles, or silver salts. These dressings are widely used on burns, diabetic foot ulcers, pressure injuries, and other exuding chronic wounds. Because collagen is a heat- and moisture-sensitive protein and ionizing radiation can degrade both the collagen structure and the antimicrobial performance of silver, low-temperature ethylene oxide (EO) sterilization is frequently selected as the terminal sterilization method for such products.

While EO sterilization is effective, EO itself is a reactive alkylating agent classified as a known human carcinogen, and its reaction by-products are also toxic. Residual EO and its primary reaction products can remain in the collagen-silver matrix after sterilization and gradually elute into the wound bed, creating a patient-safety risk. For this reason, ethylene oxide residue testing is a mandatory element of the biological safety evaluation, batch release, and regulatory documentation for these dressings.

The governing international standard is ISO 10993-7 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals), adopted in China as GB/T 16886.7. The sterilization process itself is validated under ISO 11135, and residue data also feed into chemical characterization under ISO 10993-18 and risk management under ISO 14971. The principal residual analytes are:

• Ethylene oxide (EO, CAS 75-21-8) — unreacted sterilant retained in the matrix.
• Ethylene chlorohydrin (ECH / 2-chloroethanol, CAS 107-07-3) — formed by reaction of EO with chloride species in the product, such as silver chloride or residual salts.
• Ethylene glycol (EG, CAS 107-21-1) — formed by hydrolysis of EO, monitored where required by the risk assessment.

ISO 10993-7 defines tolerable exposure limits based on cumulative patient contact duration. For wound dressings, which typically remain in contact with tissue for more than 24 hours, the applicable limits are expressed as the total residue delivered to the patient:

• Limited exposure devices (contact up to 24 hours): EO not more than 4 mg per device; ECH not more than 9 mg per device.
• Prolonged exposure devices (contact from 24 hours to 30 days): EO not more than 60 mg; ECH not more than 60 mg.
• Permanent contact devices (more than 30 days): ECH not more than 100 mg; no tolerable exposure is established for EO, so EO sterilization is generally avoided for such devices.

In practice, manufacturers convert these device-level dose limits into internal concentration acceptance criteria (for example, in micrograms per gram of dressing), taking into account the number of dressings applied simultaneously, the device mass, and the treatment duration. A specific consideration for this product category is that collagen contains nucleophilic amino acid side chains that can form slowly releasing bound residues with EO, and chloride associated with the silver component can promote ECH formation, so both analytes must be quantified with validated methods.

Testing Samples

Finished Sterilized Products

The primary sample type is the finished dressing in its final sterile barrier packaging, sampled after completion of the full validated aeration cycle. Samples should represent worst-case load positions in the sterilizer and, where applicable, cover the product family defined during process validation. Because EO dissipates over time, samples should be transported sealed, kept cool, and analyzed promptly — commonly within 30 days of sterilization — with the sterilization date, aeration parameters, and storage history fully documented.

Sterilization Validation and Cycle Development Samples

During initial qualification under ISO 11135 and during aeration-cycle optimization, samples are drawn from defined load configurations, including worst-case product and packaging arrangements. These samples establish baseline residue levels, verify that the chosen aeration temperature, time, and ventilation conditions reliably reduce EO and ECH below the acceptance criteria, and support the definition of routine release parameters.

Stability and Retention Samples

Retained samples from stability studies are tested at defined time points (for example, at release and at intervals throughout the claimed shelf life under real-time and accelerated aging conditions). This confirms that residue levels continue to meet limits over the product lifetime and that the sterile barrier system, evaluated in parallel with ISO 11607, does not trap or redistribute residuals in a way that changes patient exposure.

Material and Packaging Screening Samples

Candidate collagen-silver matrices, absorptive layers, and packaging components may be screened during design and development to identify materials with high EO affinity, so that material selection and aeration design are optimized before sterilization validation is frozen.

Testing Items

The core testing program for silver-containing collagen wound dressings includes:

• Ethylene oxide (EO) residual content, reported in micrograms per gram and as milligrams per device.
• Ethylene chlorohydrin (ECH) residual content, reported in micrograms per gram and as milligrams per device.
• Ethylene glycol (EG) content, where included in the risk assessment or requested by the manufacturer.
• Calculation of the worst-case delivered dose, comparing the measured residues against the ISO 10993-7 / GB/T 16886.7 tolerable exposure limits for the intended contact duration.
• Supporting data evaluation for batch release, sterilization validation, and regulatory submissions.

Testing Methods

Residue analysis follows the extraction and instrumental procedures recognized in ISO 10993-7, GB/T 16886.7, and GB/T 14233.1. Two extraction concepts are used, selected according to the clinical contact duration of the dressing:

• Simulated-use extraction — the product is extracted in an aqueous medium under conditions that mimic clinical use (for example, 37 °C for a period justified by the intended wound contact time), estimating the residue actually delivered to the patient.
• Exhaustive extraction — the product is extracted repeatedly until the analyte recovered in a subsequent extract falls below a defined fraction (typically no more than 10 %) of the first extract, estimating the total removable residue. This approach is particularly relevant for prolonged-contact dressings, where collagen-bound residues can continue to elute over the wear period.

The extracts are analyzed by static headspace gas chromatography:

• EO is quantified by headspace gas chromatography with flame ionization detection (HS-GC-FID) using matrix-matched or standard-addition calibration.
• ECH, which is more polar and less volatile, is determined by HS-GC-FID or, preferably, by headspace GC-MS in selected-ion monitoring mode for enhanced selectivity in the complex collagen-silver matrix.
• EG, when required, is determined by GC-MS or liquid chromatography after aqueous extraction.

Because the silver species and protein matrix can adsorb analytes or suppress headspace transfer, method performance must be demonstrated on the actual product matrix. Typical validation and quality-control parameters performed by ISO/IEC 17025 accredited third-party laboratories include:

• Calibration linearity across the working range, typically with a coefficient of determination of 0.995 or better.
• Detection and quantification limits at the sub-microgram-per-gram to low-microgram-per-gram level, well below the derived acceptance criteria.
• Spike recovery (typically within 80 % to 120 %) and replicate precision (relative standard deviation typically within 10 % to 15 %), with deactivated liners and guard columns used to control silver-related adsorption.
• Blank controls, system suitability checks, and measurement uncertainty reported alongside the results.

The final report presents residue concentrations, per-device doses, a clear pass or fail conclusion against the applicable ISO 10993-7 limits, and traceability to the sterilization and aeration records.

Applications

Ethylene oxide residue testing data for silver-containing collagen wound dressings support the full product lifecycle:

• Routine batch release testing after sterilization and aeration for every production lot.
• Initial and periodic validation of the EO sterilization process under ISO 11135, including aeration-time optimization.
• Biocompatibility and chemical characterization documentation under ISO 10993-1, ISO 10993-7, and ISO 10993-18.
• Shelf-life and stability studies confirming residue compliance throughout the claimed expiry period.
• Regulatory submissions, including national medical device registrations, US FDA premarket notifications, and EU MDR CE technical documentation.
• Risk management files under ISO 14971, documenting the toxicological assessment of residual EO, ECH, and related by-products.
• Design and development activities, such as comparing sterilization options, packaging configurations, and material formulations.
• Post-market surveillance and investigation of sterilization-related deviations or customer complaints.

FAQ

Q: Why is ethylene oxide sterilization used for silver-containing collagen dressings?

A: Collagen denatures at elevated temperatures and moisture, and radiation sterilization can fragment the collagen matrix and reduce the antimicrobial efficacy of the silver component. EO sterilization operates at low temperature, typically 37 °C to 55 °C, preserving both the protein structure and silver performance, but it leaves residues that must be controlled by testing.

Q: What is the difference between EO and ECH residues?

A: EO is the unreacted sterilizing gas retained in the product. ECH is a toxic reaction product formed when EO reacts with chloride species, which are commonly present in silver-containing systems such as silver chloride. Both analytes are regulated under ISO 10993-7 and must be quantified separately.

Q: Which limits apply to these dressings?

A: Because wound dressings usually remain in contact with tissue for more than 24 hours, the prolonged-exposure limits of ISO 10993-7 generally apply: no more than 60 mg each of EO and ECH delivered to the patient. Manufacturers typically derive far stricter internal concentration criteria in micrograms per gram to ensure a margin of safety.

Q: When should samples be tested after sterilization?

A: Testing is performed after the full validated aeration period. Since EO dissipates continuously, samples should be analyzed promptly — commonly within 30 days of sterilization — and both release testing and shelf-life time points should be covered.

Q: Do silver and collagen interfere with the analysis?

A: They can influence headspace transfer and analyte adsorption, which is why matrix-matched calibration, standard-addition calibration, GC-MS confirmation, and matrix-specific spike recovery validation are essential. A properly validated method demonstrates that these effects are controlled.

Q: How are the results reported and evaluated?

A: Results are reported as micrograms per gram and as milligrams per device, then compared with the tolerable exposure limits for the intended contact duration. The test report states a clear conformity conclusion, and accredited third-party laboratories additionally report measurement uncertainty and method traceability.

Q: Can EO residues be avoided entirely?

A: Aeration time, temperature, and airflow can be optimized during ISO 11135 validation to minimize residues, and alternative modalities such as electron-beam or gamma sterilization can be explored. However, radiation carries its own risk of collagen degradation, so any change of sterilization method must be supported by full performance and residue testing.